Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
University of Chicago
Chicago, IL
Fellowship - Hematology-Oncology
2021
McGaw Medical Center of Northwestern University
Chicago, IL
Chief Residency - Internal Medicine
2018
McGaw Medical Center of Northwestern University
Chicago, IL
Residency - Internal Medicine
2017
University of Missouri School of Medicine
Columbia, MO
MD - Medicine
2014
Northwestern University
Evanston, IL
BA - Economics
2010
Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma.
Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma. Br J Haematol. 2026 Oct 15.
PMID: 42880765
Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.
Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach. Leukemia. 2026 Sep 01.
PMID: 42680822
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study. Leukemia. 2026 Aug 31.
PMID: 42675141
Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment.
Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment. Leukemia. 2026 Aug 31.
PMID: 42675142
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia.
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
PMID: 41778833
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026 Jul 28.
PMID: 42520193
Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms.
Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms. Int J Hematol. 2026 Jul 21.
PMID: 42481866
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 Sep; 44(25):2422-2434.
PMID: 42391582
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026. J Natl Compr Canc Netw. 2026 Jul; 24(7).
PMID: 42425157
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy. Leuk Lymphoma. 2026 Aug; 67(10):2064-2072.
PMID: 42281276